Expert's Opinion
-
Biologics, Proteins, Vaccines | Drug Development
The Missing Piece in Rare-Disease Drug Development
More genetics expertise is crucial in getting these drugs to market.Jill Johnston, President, Site Activation Solutions, WCG Clinical Services and Karmen Trzupek, Director, Ocular & Rare Disease Genetics Services, InformedDNA 08.22.18
-
Biosimilars
Navigating Uncertainty in Biosimilar Drug Development
Bryan Katz of Syneos Health and Brittany Scott of Addison Whitney share insights from DIABryan Katz, Vice President Integrated Solutions, Syneos Health and Brittany Scott, Creative Director, Addison Whitney, a Syneos Health company 07.11.18
-
Clinical Trials | Drug Development | Regulatory Affairs
Are EMA-Style Rules for First-in-Human Trials Coming to North America?
Insights from the 2018 DIA Global MeetingBeatrice Setnik, Ph.D., Vice President, Scientific and Clinical Strategy, Early Phase, Syneos Health 07.03.18
-
Biologics, Proteins, Vaccines
Technological Arms Race Could Improve Bio Process Mfg. Efficiency
Experts warn bio industry needs to do more to create a sustainable pipeline of talent06.29.18
-
Clinical Trials | Drug Development | Industry News | Information Technology
Ready for ASCO
Why ASCO’s annual meeting is one of the most important events in the oncology communityDr. Eric Groves, Vice President of Strategic Drug Development, R&D Solutions, IQVIA 06.01.18
-
Drug Discovery
Developing a Translational Immuno-oncology Platform
The critical bridge supporting a project’s transition from the bench to clinicMartin O’Rourke, Ph.D., Senior Director, Oncology In Vitro Biosciences, Integrated Drug Discovery at Charles River 05.03.18
-
Bio News | Biosimilars
Know the Challenges of Biosimilar Manufacturing
Best Practices for a Competitive MarketJerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18
-
Clinical Trials
The Objective is to Be Objective
Steering toward more reliable data in dermatology clinical trialsDarcee Duke Strube 03.05.18
-
-
Biosimilars | Drug Development
Differentiating in the Biosimilar Market: Surviving the Cost of Entry
Companies need to improve customer experience, produce additional evidence, and create valuable engagement with stakeholdersMichael Turner and Magnus Franzen, Life Sciences Experts, PA Consulting Group 03.01.18
-
Drug Development | Information Technology
Five Digital Trends Transforming the Life Sciences Industry
Putting patients at the heart of innovation12.05.17
-
Biologics, Proteins, Vaccines
Analyzing Developments in the CAR-T Field
A detailed look at opportunities and limitations of current T-cell therapiesDr. John Savin, B.Sc, Ph.D., MBA, analyst at Edison Investment Research Ltd. 11.13.17
-
Clinical Trials | Drug Development | Information Technology
Leveraging EHR Data to Support Clinical Trials
Technology now exists to free up EHR data and streamline the clinical trial processDr. Manfred Stapff, Chief Medical Officer, TriNetX 11.06.17
-
Fill/Finish | Lyophilization
Primary Containment Trends in Lyophilization
Plastic caps for aseptic crimping can reduce unwanted interactionsSylvia Marzotko, Senior Manager Product Management, West 10.25.17
-
APIs
Biocatalysis for APIs
Engineered enzymes pave easier, faster road to scalable API manufacturingMichael Aldridge, SVP of Corporate and Strategic Development, Codexis 09.12.17
-
Clinical Trials | Drug Development | Information Technology
Evolution of the CRO Project Manager
As clinical project managers become more strategic, more advanced technology must support their evolving rolesAndy Mehrotra, CEO, EightSpokes 08.31.17
-
Clinical Trials | Drug Development
CRO Competition Heats Up: Differentiate Offerings to Retain Site Loyalty
Site centricity becomes even more critical with increased CRO competition and M&ADave Espenshade, Vice President of CRO Partnerships, Greenphire 07.25.17
-
Bioanalytical Services | Biosimilars
The Analytical Challenges of the Biosimilar Boom
The growing biosimilar industry and its implications on the current drug marketMario DiPaola, Senior Scientific Director, Charles River Laboratories 07.03.17
-
Clinical Trials | Drug Development | Drug Discovery | Information Technology
When Big Data is Not Enough
Leveraging real-world data and advanced analytics to develop more targeted recruiting strategies for rare diseasesAdina Knight , Medical Director and Medical Strategy Lead at QuintilesIMS 06.16.17
-
Drug Delivery
Opportunity Knocks for Inhalers in Emerging Markets
As key drugs and delivery devices come off-patent emerging markets offer potential for inhaled genericsDr. Anselm Ebert, Global Business Development Manager, H&T Presspart 06.05.17
